type 2 diabetic patients. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Transcranial direct stimulation for two weeks every other day with an intensity of 20 mA for 20 minutes in the F4 and F3 areas of the head without any dietary recom
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Previously diagnosed T2DM (HbA1C= 6.5% or FPG= 126 mg/dl or OGTT> 200 mg/dl) Age > 18 years and 30
Exclusion criteria
Exclusion criteria: Unwillingness or inability to complete any of the major aspects of the study protocol including food cue rating or behavioral assessments Previously diagnosed psychiatric disorders (i.e., depression, psychotic disorders, personality disorders, dementia-related disorders) Presence of eating disorders evaluated by Eating Disorder Examination Questionnaire History of cancer, stroke, and renal, cardiovascular, or liver diseases Use dietary supplements at the start of study or during last 3 months Using appetite increasing or suppressing drugs Any other condition the research team feel would put the subject at risk for entering the study Contraindication to tDCS (pacemaker, a metal embedded in the scalp or brain, skin lesions at the site of stimulation, history of head injury or neurosurgery, and seizures)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Food craving. Timepoint: Before intervention, day 14, day 30, day 60, day 90 after intervention. Method of measurement: Food Craving Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting plasma glucose. Timepoint: Before intervention, day 14, day 90 after intervention. Method of measurement: enzymatic UV-hexokinase.;Glycated hemoglobin A1C. Timepoint: Before intervention, day 14, day 90 after intervention. Method of measurement: high-performance liquid chromatography.;Serum Insulin. Timepoint: Before intervention, day 14, day 90 after intervention. Method of measurement: chemiluminescence microparticle immunoassay.;Weight. Timepoint: Before intervention, day 14, day 30, day 60, day 90 after intervention. Method of measurement: Scale.;Body composition. Timepoint: Before intervention, day 14, day 30, day 60, day 90 after intervention. Method of measurement: InBody 353 tetrapolar body composition analyzer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhossein Ramezani Ahmadi
Esfahan University of Medical Sciences
Outcome results
None listed